• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Authors » Daniel Carlat, MD

Daniel Carlat, MD

Dr. Carlat has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Articles
Products

ARTICLES

1767701223649.jpeg

Difficult-to-Treat Depression

February 19, 2026
Daniel Carlat, MD

Depression distorts memory. Measurement restores it. 




Read More
1767374156178.jpeg

Flow Device: FDA Approval vs Real-World Effectivenes

February 9, 2026
Daniel Carlat, MD

In December 2025, Flow did in fact receive FDA Approval, based on data from the Empower trial. Before that, it had been marketed under FDA clearance—a lower evidentiary bar. That correction matters—and it sharpens the question many subscribers have been asking me: How much does FDA approval tell us about real‑world effectiveness?




Read More
1766069397913.jpeg

Psychodynamic Therapy

January 29, 2026
Daniel Carlat, MD

Psychodynamic therapy isn’t outdated.
It’s evolving. Grounded in evidence.




Read More
1763987110807.jpeg

ADHD Today

January 4, 2026
Daniel Carlat, MD

In the latest issue of TCPR, we give a lot of real estate to ADHD.
And for good reason. It’s a diagnosis that’s everywhere—expanding across age groups, personality types, and practice settings.




Read More
Fact Sheet

Prazosin (Minipress) Fact Sheet for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Prazosin is an alpha-1 antagonist (FDA approved for hypertension) that has become popular as a treatment for insomnia/nightmares associated with post-traumatic stress disorder (PTSD). 




Read More
Fact Sheet

N-Acetylcysteine (NAC) Fact Sheet for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

NAC is a glutamate modulator derived from the amino acid cysteine. It’s been tested in many psychiatric conditions, but shows the most promise as an adjunctive treatment to selective serotonin reuptake inhibitors for compulsive behaviors like obsessive-compulsive disorder (OCD), trichotillomania, nail biting, and skin picking. Evidence is modest but encouraging.




Read More
Fact Sheet

Lorazepam (Ativan, Loreev XR) Fact Sheet for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

When a benzodiazepine is appropriate for use (short term; minimal risk of abuse), we consider lorazepam to be a first-line agent.




Read More
Fact Sheet

Flurazepam (Dalmane) Fact Sheet for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Flurazepam is an older benzodiazepine that has fallen out of favor due to its very long half-life and its active metabolites.




Read More
Fact Sheet

Diazepam (Valium) Fact Sheet for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Diazepam is a long-acting benzodiazepine useful for anxiety, alcohol withdrawal, muscle spasms, and seizures. 




Read More
Fact Sheet

Alprazolam (Xanax) Fact Sheet for General Psychiatry

January 1, 2026
Daniel Carlat, MD and Talia Puzantian, PharmD, BCPP

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Alprazolam is fast acting and effective for generalized anxiety disorder (GAD) and panic disorder, but its short duration of action may contribute to breakthrough symptoms between doses and make withdrawal more difficult.




Read More
View All Articles by Daniel Carlat, MD
Try The New AskCarlat AI

Ask any clinical question—our AI responds using only the peer-reviewed, editorially vetted content from Carlat Publishing.

Available In The Carlat Toolkit
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
  • MFB8e_SpiralCover.png

    Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

    Updated 2026 prescriber's guide.
    READ MORE
Featured Video
  • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
    General Psychiatry

    KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

    Read More
Featured Podcast
  • RogerSolomon2023.jpg
    General Psychiatry

    EMDR in Practice: A Clinician's Guide to Trauma Reprocessing with Roger Solomon, PhD

    Dr. Roger Solomon provides a comprehensive introduction to Eye Movement Desensitization and Reprocessing (EMDR).

    Listen now
Recommended
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png
  • Join Our Writing Team

    July 18, 2024
    WriteForUs.png
  • Insights About a Rare Transmissible Form of Alzheimer's Disease

    February 9, 2024
    shutterstock_2417738561_PeopleImages.com_Yuri A.png
  • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

    May 24, 2024
    DEA_Checkbox.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report
  • The Carlat Psychotherapy Report

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.